

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
13 January 2005 (13.01.2005)

PCT

(10) International Publication Number
WO 2005/003092 A1

(51) International Patent Classification⁷: **C07D 211/32**,
211/04, 211/02

LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD,
SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US,
UZ, VC, VN, YU, ZA, ZM, ZW.

(21) International Application Number:
PCT/IN2003/000232

(22) International Filing Date: 1 July 2003 (01.07.2003)

(25) Filing Language: English

(26) Publication Language: English

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (for all designated States except US): **HETERO
DRUGS LIMITED** [IN/IN]; Hetero House, 8-3-166/7/1,
Erragadda, Hyderabad, Andhrapradesh 500 018, Hyder-
abad (IN).

(72) Inventors; and

(75) Inventors/Applicants (for US only):
PARTHASARADHI REDDY, Bandi [IN/IN];
Hetero House, 8-3-166/7/1, Erragadda, Hyderabad,
Andhrapradesh 500 018, Hyderabad (IN). **RATHNAKAR
REDDY**, Kura [IN/IN]; Hetero Drugs Limited (R
& D), Plot No. B-80 & 81, A.P.I.E., Balanagar,
Hyderabad, Andhrapradesh 500 018, Hyderabad (IN).
RAJI REDDY, Rapolu [IN/IN]; Hetero Drugs Limited
(R & D), Plot No. B-80 & 81, A.P.I.E., Balanagar,
Hyderabad, Andhrapradesh 500 018, Hyderabad (IN).
MURALIDHARA REDDY, Dasari [IN/IN]; Hetero
Drugs Limited (R & D), Plot No. B-80 & 81, A.P.I.E.,
Balanagar, Hyderabad, Andhrapradesh 500 018,
Hyderabad (IN).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted
a patent (Rule 4.17(ii)) for the following designations AE,
AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG,
KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK,
MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU,
SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG,
UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR,
GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR),
OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
ML, MR, NE, SN, TD, TG)
- of inventorship (Rule 4.17(iv)) for US only

Published:

- with international search report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: PREPARATION OF INTERMEDIATES FOR ACETYL CHOLINESTERASE INHIBITORS

(57) Abstract: A simple, industrial process for the preparation of the intermediates of acetyl cholinesterase inhibitors is provided. Thus, for example, 5,6-dimethoxy-2-(4-pyridyl)methyl-1-indanone is hydrogenated using platinum oxide catalyst in the presence of hydrochloric acid under a pressure of 2 bars to give 4-[(5,6-dimethoxy-1-indanon)-2-yl] methylpiperidine hydrochloride, which is then converted to donepezil hydrochloride, an acetyl cholinesterase inhibitor.

WO 2005/003092 A1

BEST AVAILABLE COPY

PREPARATION OF INTERMEDIATES FOR ACETYL CHOLINESTERASE
INHIBITORS

FIELD OF THE INVENTION


5 The present invention provides a simple and cost effective process for the preparation of intermediates for acetyl cholinesterase inhibitors.

BACKGROUND OF THE INVENTION

10 US 4,895,841 and US 6,277,866 disclosed piperidine derivatives having excellent anti acetyl cholinesterase activity. These compounds are effective for treatment and prevention of diseases such as Alzheimer senile dementia, Huntington's chorea, Pick's disease and ataxia. Of these compounds, donepezil hydrochloride, 1-benzyl-4-[(5,6-dimethoxy-1-indanon-2-yl)methyl]piperidine hydrochloride is a well known acetyl cholinesterase inhibitor and is on the
15 market as Aricept for the treatment of Alzheimer disease.


 According to the process disclosed in US 4,895,841, 5,6-dimethoxy-1-indanone was condensed with 1-benzyl-4-formylpiperidine in the presence of lithium diisopropylamide to give 5,6-dimethoxy-2-[[1-benzyl-4-piperidinyl]methylene]-1-indanone, which was then reduced with platinum oxide
20 catalyst to give donepezil.

 1-Benzyl-4-formylpiperidine is not available and difficult to synthesize commercially. Moreover the combined yield is very low.



US 5,606,064 disclosed a process for the preparation of donepezil. 5,6-dimethoxy-1-indanone was condensed with pyridin-4-aldehyde to give 5,6-dimethoxy-2-(pyridin-4-yl)methyleneindan-1-one, reacted with benzyl bromide to give 1-benzyl-4-(5,6-dimethoxyindan-1-on-2-ylidene)methylpyridinium bromide and then, hydrogenated in the presence of platinum oxide catalyst to yield donepezil.


The yield of the hydrogenation of pyridinium salt is 81%.



10

According to WO 9722584, methyl 4-[2-(3,4-dimethoxybenzoyl)allyl]piperidin-1-carboxylate is cyclized in the presence of sulfuric acid to give methyl 4-(5,6-dimethoxy-1-oxoindan-2-ylmethyl)piperidin-1-carboxylate, decarboxylated and then treated with benzyl bromide to give donepezil.

Preparation of methyl 4-[2-(3,4-dimethoxybenzoyl)allyl]piperidin-1-carboxylate intermediate itself involve many stages thereby resulting in very low overall yield.




5

According to US 6,252,081, 5,6-dimethoxy-2-methoxycarbonyl-1-indanone is reacted with 4-pyridinylmethyl chloride to give 5,6-dimethoxy-2-(4-pyridyl)methyl-2-methoxycarbonyl-1-indanone, decarboxylated to give 5,6-dimethoxy-2-(4-pyridyl)methyl-1-indanone then, reacted with benzyl bromide to give 1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl]methylpyridinium bromide followed by catalytic hydrogenation to yield donepezil.

10

The process involves introduction of methoxy carbonyl group and decarboxylation steps, thereby making the process very lengthy.



Indanone derivatives of the formula I are useful intermediates for the preparation of acetyl cholinesterase inhibitors of the formula III. The major problem with the preparation of the compounds of the formula I by the catalytic hydrogenation of the compound of the formula II is that high pressures are required and that under these conditions carbonyl group is also reduced to alcohol.

We have found that the compounds of the formula II can be selectively hydrogenated to yield the compounds of the formula I using hydrogenating catalyst under a suitable condition. The yields and purities are found to be very good.


The intermediates of the formula I can be converted to the compounds of formula III by the method described in example 180 of EP 296560 and WO 9722584.

The compounds of the formula II can be easily and cheaply obtained from the processes described in J. Heterocyclic Chem. 2(4), 366-370 (1965) and US 5,606,064.


Thus, the present invention provides a simple, cost effective and industrial process for the preparation of the compounds of the formula III via the intermediates of the formula I and overcomes the problems of the prior art processes.

SUMMARY OF THE INVENTION

The present invention provides a process for preparing the compound of the general formula I or a salt thereof:



wherein R represents, the same as or different from each other, a hydrogen atom or a lower alkoxy group, n represents an integer of 1 to 4 and Y represents H or F, which comprises the hydrogenation of the compound of the general formula II:



wherein R, n and Y have the same meaning as defined above, with hydrogen using platinum oxide, palladium-carbon, raney nickel or ruthenium oxide catalyst in the presence of an acid under a hydrogen pressure of 1 to 10 bars and optionally converting the compound of the formula I to the salt.

Lower alkoxy group herein means a straight or branched lower alkyl group having 1 to 6 carbon atoms bonded with oxygen atom.

Preferably, 0.1 to 10 moles of the acid per mole of the compound of formula II, more preferably 0.5 to 5 moles of the acid per mole of the compound of formula II is used.

Preferable acids are hydrochloric acid, sulfuric acid, phosphoric acid and
5 acetic acid.


Hydrogen pressure is maintained preferably between about 1 to 6 bars and more preferably between about 1 to 4 bars.

The catalyst is usually present in an amount from about 0.01 to about 25 weight-percent, and preferably from about 0.1 to about 10 weight -percent,
10 based on the compound of the formula II. Platinum oxide is the preferred catalyst.

Preferable salt of the compound of the formula I is hydrochloric acid salt.

The compounds of the formula I, wherein n is 1-3, R is methoxy or ethoxy and Y is H are preferred compounds.

15 The present invention also provides the preparation of an acetyl cholinesterase inhibitor of the formula III:



wherein R represents, the same as or different from each other, a hydrogen atom or a lower alkoxy group, n represents an integer of 1 to 4 and Y represents
20 H or F,
which comprises reacting the compound of the formula I with a benzyl halide.

Lower alkoxy group herein means a straight or branched lower alkyl group having 1 to 6 carbon atoms bonded with oxygen atom.

The halide is selected from chloride, bromide and iodide. The preferable
25 halide is chloride or bromide.


The compounds of the formula III, wherein n is 1-3, R is methoxy or ethoxy and Y is H are preferred compounds.

Lower alkoxy group herein means a straight or branched lower alkyl group having 1 to 6 carbon atoms bonded with oxygen atom.

DETAILED DESCRIPTION OF THE INVENTION


The present invention provides a process for preparing compounds of the general formula I or a salt thereof:

5



wherein R represents, the same as or different from each other, a hydrogen atom or a lower alkoxy group, n represents an integer of 1 to 4 and Y represents H or F,

10 which comprises the selective hydrogenation of the compound of the general formula II:



wherein R, n and Y have the same meaning as defined above and optionally
15 converting the compound of the formula I to the salt.

Lower alkoxy group herein means a straight or branched lower alkyl group having 1 to 6 carbon atoms bonded with oxygen atom; methoxy, ethoxy and 5,6-dimethoxy groups being preferable.

The selective hydrogenation is carried out employing platinum oxide,
20 palladium-carbon, raney nickel or ruthenium oxide catalyst. Platinum oxide is particularly preferred catalyst.

The hydrogenation takes place in a suitable solvent in the presence of an acid under a hydrogen pressure of 1 to 10 bars, preferably of 1 to 6 bars and more preferably of 1 to 4 bars at the temperature of 15°C to 100°C, preferably of
25 20°C to 35°C.

Examples of the suitable solvents for the hydrogenation are alcohols such as methanol or ethanol, acetonitrile, tetrahydrofuran, dimethylformamide, dimethylsulfoxide, dioxane, aromatic hydrocarbons such as benzene, toluene, xylene, etc., halogenated hydrocarbons such as dichloromethane, chloroform, carbontetrachloride, etc., ketones such as acetone, methyl ethyl ketone, ethyl isobutyl ketone, etc., ethers such as tert-butyl methyl ether, or carboxylates such as ethyl acetate. A mixture of the solvents may also be used.

Preferable acid used in the hydrogenation is hydrochloric acid, sulfuric acid, phosphoric acid or acetic acid. Hydrochloric acid is more preferred and the product obtained is hydrochloric acid salt if the acid used is hydrochloric acid.

Hydrogenation is carried out in a conventional manner known in the art. Hydrogen gas is usually introduced into a hydrogenation flask containing the compound of the formula II, the solvent, the acid and the catalyst.

Utilizing the preferred temperature and pressure values, hydrogenation generally takes place in a few hours, e.g., from about 0.5 hour to about 36 hours.

When the hydrogenation is substantially complete, the desired product of the formula I is then isolated by standard methods, e.g., the catalyst is removed by filtration, the solvent evaporated and the product purified, if desired, by well-known methods such as crystallization or by chromatography.


The catalyst is usually present in an amount from about 0.01 to about 25 weight-percent, and preferably from about 0.1 to about 10 weight -percent, based on the compound of the formula II.

The compounds of the formula I, wherein n is 1-3, R is methoxy or ethoxy and Y is H are preferred compounds.

The preferred compounds of the formula I or the salts thereof are:

- 4-[(5,6-dimethoxy-1-indanon)-2-yl]methylpiperidine,
- 4-[(6-methoxy-1-indanon)-2-yl]methylpiperidine,
- 4-[(5-methoxy-1-indanon)-2-yl]methylpiperidine,
- 4-[(5,7-dimethoxy-1-indanon)-2-yl]methylpiperidine,
- 4-[(6,7-dimethoxy-1-indanon)-2-yl]methylpiperidine and
- 4-[(5,6-dimethoxy-2-fluoro-1-indanon)-2-yl]methylpiperidine.

The compounds of the formula I are useful for the preparation of the compounds of the formula III:



wherein R represents, the same as or different from each other, a hydrogen atom or a lower alkoxy group, n represents an integer of 1 to 4 and Y represents H or F.

Lower alkoxy group herein means a straight or branched lower alkyl group having 1 to 6 carbon atoms bonded with oxygen atom; methoxy, ethoxy and 5,6-dimethoxy groups being preferable.

The compounds of the formula III can be prepared from the compounds of formula I by reacting the compounds of formula I with a benzyl halide. The halide is chloride, bromide or iodide. The preferable halide is chloride or bromide. The reaction steps for the synthesis of the compounds of the formula III are shown in the scheme shown below.


The compounds of the formula III, wherein n is 1-3, R is methoxy or ethoxy and Y is H are preferred compounds.

Lower alkoxy group herein means a straight or branched lower alkyl group having 1 to 6 carbon atoms bonded with oxygen atom, methoxy and 5,6-dimethoxy groups being preferable.

Preferred compounds of the formula III or the salts thereof are:

- 1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl]methylpiperidine,
- 1-benzyl-4-[(6-methoxy-1-indanon)-2-yl]methylpiperidine,
- 1-benzyl-4-[(5-methoxy-1-indanon)-2-yl]methylpiperidine,
- 1-benzyl-4-[(5,7-dimethoxy-1-indanon)-2-yl]methylpiperidine,
- 1-benzyl-4-[(6,7-dimethoxy-1-indanon)-2-yl]methylpiperidine and
- 1-benzyl-4-[(5,6-dimethoxy-2-fluoro-1-indanon)-2-yl]methylpiperidine.

Scheme:



The invention will now be further described by the following examples;
 5 which are illustrative rather than limiting.

Example 1

The mixture of 5,6-dimethoxy-2-(4-pyridyl)methylene-1-indanone (34
 10 gm), methanol (325 ml), methylenedichloride (200 ml) and 5% palladium-
 charcoal (2 gm) is taken in a hydrogenation flask and subjected to
 hydrogenation under a hydrogen pressure of 2 bars for 3 hours. The catalyst is
 removed by filtration and the solvents are evaporated completely under vacuum
 to obtain a residue. Ethyl acetate (150 ml) is added to the residue and stirred for
 15 20 minutes at 25°C to 30°C. The contents are then cooled to 0°C, stirred for 30

minutes and filtered to give 34 gm of 5,6-dimethoxy-2-(4-pyridyl)methyl-1-indanone.

Example 2


5 The mixture of 5,6-dimethoxy-2-(4-pyridyl)methyl-1-indanone (45 gm), methanol (600 ml), concentrated hydrochloric acid (18 ml) and platinum oxide catalyst (2.5 gm) is taken into a hydrogenation flask and subjected to hydrogenation under a hydrogen gas pressure of 2 bars for 5 hours. The catalyst is filtered off and the solvents are evaporated completely under vacuum.
10 Ethyl acetate (150 ml) is added to the residue and stirred for 15 minutes at 25°C to 30°C. Then the contents are cooled to 0°C, stirred for 30 minutes and filtered to give 48 gm of 4-[(5,6-dimethoxy-1-indanon)-2-yl]methylpiperidine hydrochloride.

Example 3

15 Benzyl bromide (4.5 ml) is added to the mixture of 4-[(5,6-dimethoxy-1-indanon)-2-yl]methylpiperidine hydrochloride (8 gm), toluene (150 ml) and potassium carbonate (9 gm) and stirred for 2 hours at 25°C 30°C. The reaction mass is cooled to 10°C and filtered. The filtrate is washed with water, dried over
20 sodium sulfate and concentrated under vacuum. Ethyl acetate (200 ml) is added to the residue, stirred for 10 minutes at 25°C 30°C, cooled to 0°C and hydrogen chloride gas is passed till the pH 2 is attained. The reaction is maintained for 30 minutes at the same temperature. The solid is filtered, washed with ethyl acetate and dried under vacuum at 50°C for 4 hours to give 8 gm of donepezil
25 hydrochloride.


We claim:

- 1) A process for the preparation of the compound of the general formula I or a salt thereof:



wherein R represents, the same as or different from each other, a hydrogen atom or a lower alkoxy group, n represents an integer of 1 to 4 and Y represents H or F,


- 10 which comprises hydrogenating the compound of the general formula II:



wherein R, n and Y have the same meaning as defined above, with hydrogen using platinum oxide, palladium-carbon, raney nickel or ruthenium oxide catalyst
15 in the presence of an acid under a hydrogen pressure of 1 to 10 bars and optionally converting the compound of the formula I to the salt.

- 2) A process according to claim 1, wherein R is methoxy or ethoxy; n is 1-3; and Y is fluorine or hydrogen.
- 3) A process according to claim 1, wherein the compound of the formula I is 4-
20 [(5,6-dimethoxy-1-indanon)-2-yl]methylpiperidine or a salt thereof.
- 4) A process according to claim 1, wherein 0.1 to 10 moles of the acid per mole of the compound of formula II is used.
- 5) A process according to claim 4, wherein 0.5 to 5.0 moles of the acid per mole of the compound of formula II is used.
- 25 6) A process according to claim 1, wherein the acid is selected from hydrochloric acid, sulfuric acid, phosphoric acid and acetic acid.
- 7) A process according to claim 6, wherein the acid is hydrochloric acid.

- 8) A process according to claim 1, wherein the catalyst is platinum oxide.
- 9) A process according to claim 1, wherein the pressure is about 1 to 6 bars.
- 10) A process according to claim 9, wherein the pressure is about 1 to 4 bars.
- 11) A process according to claim 1, further comprises reacting the product of the claim 1 with a benzyl halide, wherein halide is bromide, chloride or iodide to give a compound of the formula III or a salt thereof:



wherein R, n and Y has the same meaning as defined in claim 1.

- 12) A process according to claim 11, wherein R is methoxy or ethoxy and n is 1 to 3.
- 13) A process according to claim 12, wherein the compound of the formula III is 1-benzyl-4-[(5,6-dimethoxy-1-indanon-2-yl)methyl]piperidine or hydrochloride salt thereof.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/IN 03/00232-0

CLASSIFICATION OF SUBJECT MATTER

IPC⁷: C07D 211/32, C07D 211/04, C07D 211/02

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC⁷: C07C, C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CASREACT, CAPLUS, WPI, EPODOC

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
E,X	US 6649765 B1 (Vidyadhar et al.) 18 November 2003 (18.11.2003) column 3, lines 10-35.	1-13
A	WO 1999/036405 (EISAI CO., LTD) 22 July 1999 (22.07.1999) pp. 22 - 23, under "(5) Step 5".	1-13
A	US 6492522 B1 (Gutman et al.) 10 December 2002 (10.12.2002)	1-13

☐ Further documents are listed in the continuation of Box C.☒ See patent family annex.

* Special categories of cited documents:

„A“ document defining the general state of the art which is not considered to be of particular relevance

„E“ earlier application or patent but published on or after the international filing date

„L“ document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

„O“ document referring to an oral disclosure, use, exhibition or other means

„P“ document published prior to the international filing date but later than the priority date claimed

„T“ later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

„X“ document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

„Y“ document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

„&“ document member of the same patent family

Date of the actual completion of the international search

24 February 2004 (24.02.2004)

Date of mailing of the international search report

23 March 2004 (23.03.2004)

Name and mailing address of the ISA/AT

Austrian Patent Office

Dresdner Straße 87, A-1200 Vienna

Facsimile No. 1/53424/535

Authorized officer

GÖRNER W.

Telephone No. 1/53424/0

Form PCT/ISA/210 (second sheet) (July 1998)

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/IN 03/00232-0

Patent document cited In search report			Publication date	Patent family member(s)			Publication date
US	B	6492522	2002-12-10	JP	T	2002525264T	2002-08-13
				HU	A	0103253	2002-01-28
				EP	A	1129073	2001-09-05
				WO	A	0009483	2000-02-24
				AU	A	5191099	2000-03-06
US	B	6649765	2003-11-18	none			
WO	A	19990364 05		none			

pat- In-022-05

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☒ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.